Core Viewpoint - Enhua Pharmaceutical reported a revenue of 4.471 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 7.85% [1] - The net profit attributable to shareholders reached 1.106 billion yuan, marking an increase of 8.42% compared to the previous year [1] Financial Performance - Revenue for the first three quarters: 4.471 billion yuan, up 7.85% year-on-year [1] - Net profit attributable to shareholders: 1.106 billion yuan, up 8.42% year-on-year [1]

Group 1 - Enhua Pharmaceutical held its seventh fourth board meeting on October 24, 2025, in Xuzhou, where the third quarter report for 2025 was reviewed [1] - The company reported that it has sold overseas authorizations worth $80 billion in the current year [1] - The secondary market for biopharmaceuticals is experiencing a surge, while the primary market is facing challenges in fundraising [1]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 4.471 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.85% [1] - The net profit attributable to shareholders of the listed company reached 1.106 billion yuan, with a year-on-year increase of 8.42% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.109 billion yuan, reflecting a year-on-year growth of 7.59% [1]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 4.47 billion yuan for the first three quarters, representing a year-on-year growth of 7.85% [1] - The net profit attributable to shareholders reached 1.106 billion yuan, with a year-on-year increase of 8.42% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.109 billion yuan, reflecting a year-on-year growth of 7.59% [1]

人民财讯10月24日电，恩华药业(002262)10月24日披露2025年三季度报告，公司第三季度实现营业收入 14.61亿元，同比增长5.70%；归母净利润4.06亿元，同比增长3.67%。前三季度实现营业收入44.71亿 元，同比增长7.85%；归母净利润11.06亿元，同比增长8.42%。 转自：证券时报 ...

Core Insights - Enhua Pharmaceutical reported Q3 revenue of 1.461 billion yuan, a year-on-year increase of 5.70% [1] - The net profit for Q3 was 406 million yuan, reflecting a year-on-year growth of 3.67% [1] - For the first three quarters, the total revenue reached 4.471 billion yuan, up by 7.85% year-on-year [1] - The net profit for the first three quarters was 1.106 billion yuan, showing an increase of 8.42% year-on-year [1]

第七届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 江苏恩华药业股份有限公司（以下简称：公司）监事会于2025年10月13日以电子邮 件及专人送达的方式向全体监事发出召开第七届监事会第四次会议的通知及相关会议资 料。2025年10月24日下午1：00至3：00，第七届监事会第四次会议在徐州市经济技术开 发区龙湖西路31号恩华科技大厦20楼会议室以现场表决的方式召开，公司3名监事全部参 加了会议。本次会议由监事会主席王丰收先生主持。本次会议的召集、召开程序符合有 关法律法规和公司章程的规定。 二、监事会会议审议情况 1、会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2025年第三季 度报告》。 证券代码：002262 证券简称：恩华药业 公告编号：2025-052 江苏恩华药业股份有限公司 经审核，监事会认为：董事会编制和审核公司2025年第三季度报告的程序符合法律、 行政法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了报告期内公司 的财务状况、经营成果和现金流量，不存在任何虚假记载、 ...

证券代码：002262 证券简称：恩华药业 公告编号：2025-051 江苏恩华药业股份有限公司 第七届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 一、董事会会议召开情况 江苏恩华药业股份有限公司（以下简称"公司"）第七届董事会第四次会议于 2025 年 10 月 24 日在徐州市经济技术开发区龙湖西路 31 号恩华科技大厦 20 楼会议室召开，会议通知已 于 2025 年 10 月 13 日以专人送达、传真、电子邮件等方式送达给全体董事、监事和高级管理 人员。本次会议应到董事 8 名，实到董事 8 名。公司监事和高级管理人员亦列席本次会议。 本次会议由董事长孙彭生先生召集并主持。本次会议的召集、召开程序符合有关法律法规和 公司章程的规定。 1、会议以8票赞成、0票反对、0票弃权的表决结果审议通过了《2025年第三季度报告》。 董事会及全体董事保证《2025 年第三季度报告》内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 《2025年第三季度报告》（公告编号：2025-053） ...

江苏恩华药业股份有限公司 2025 年第三季度报告 证券代码：002262 证券简称：恩华药业 公告编号：2025-053 江苏恩华药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 江苏恩华药业股份有限公司 2025 年第三季度报告 单位：元 项目 本报告期金额 年初至报告期期末金额 说明 非流动性资产处置损益（包 括已计提资产减值准备的冲 销部分） 22,161.91 -319,529.13 计入当期损益的政府补助 （与公司正常经营业务密切 相关、符合国家政策规定、 按照确定的标准享有、对公 司损益产生持续影响的政府 补助除外） 458,808.32 1,566,456.32 除上述各项之外的 ...

Investment Rating - The report maintains a positive outlook on the innovative drug and medical device industry, highlighting key targets for investment [5][24]. Core Insights - The innovative drug sector is experiencing high growth, with a focus on companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. The report emphasizes the potential for value re-evaluation in these firms [5][24]. - Recent business development (BD) deals in the innovative drug sector are expected to catalyze market activity, with notable transactions including Jiangsu Heng Rui Medicine's agreement with Kite for a $1.20 billion upfront payment, potentially reaching $15.20 billion in total [5][24]. - The A-share pharmaceutical sector underperformed the broader market in the third week of October 2025, with the Shanghai Composite Index falling by 1.5% and the SW Biopharma index declining by 2.5% [7][18]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Medical Devices - The report emphasizes the high growth potential in innovative drugs, with key investment targets including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. Related targets include CSPC Innovation Pharmaceutical [5][24]. 2. A-Share Pharmaceutical Sector Performance - In the third week of October 2025, the A-share pharmaceutical sector saw a decline of 2.5%, underperforming the Shanghai Composite Index, which fell by 1.5%. The report notes that the sector's premium relative to all A-shares is currently at a normal level, with a relative premium rate of 74.5% [7][14][21]. 3. Hong Kong and U.S. Pharmaceutical Sector Performance - The report indicates that the Hong Kong and U.S. pharmaceutical sectors also underperformed, with the Hang Seng Healthcare index dropping by 5.8% and the S&P 500 Healthcare index increasing by only 0.7% during the same period [18][24].